Elliott Carr Cutler Professor of Surgery, Brigham and Women's Hospital
Urology
Dr. Jerome P. Richie, MD
|
|
Give Review
Jerome Richie works in the field of Urology. He has 7 awards "America's Top Doctors", "Boston Magazine", "America's Top Doctors for Cancer", "Boston Herald", "Fellow (FACS)", "Top MD" and "Super Doctor". Dr. Jerome P. Richie is a published physician as well. He has 78 publications published. The latest was: Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Re: Presence of Teratoma in Orchiectomy Specimen Increases the Need for Postchemotherapy RPLND.
- Re: public perceptions of the harms and benefits of testicular Cancer education: a qualitative study.
- Commentary on "Screening for testicular Cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement." Collaborators (18), U.S. Preventive Servic...
- Commentary on "Survival after resection for metastatic testicular nonseminomatous germ cell Cancer to the lung or mediastinum." Kenneth A. Kesler,(a) Laura E. Kruter,(...
- Commentary on "Partial orchiectomy for presumed malignancy in patients with a solitary testis due to a prior germ cell tumor: A large North American experience." Lawre...
- Commentary on "Successful treatment of post-chemotherapy azoospermia with microsurgical Testicular sperm extraction: The Weill Cornell experience." Hsiao W, Stahl PJ, ...
- Re: management of seminomatous testicular Cancer: a binational prospective population-based study from the Swedish norwegian testicular Cancer study group.
- Autoantibody signatures as biomarkers to distinguish prostate Cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
- Introduction: International consultation on urologic diseases: testicular Cancer: Societe Internationale d'Urologie/International Consultation on Urologic Diseases Con...
- Urological oncology: testis Cancer.
- Radical retropubic Prostatectomy and robotic-assisted laparoscopic Prostatectomy: likelihood of positive surgical margin(s).
- Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy.
- Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis Cancer.
- Radical Prostatectomy reigns supreme.
- Retroperitoneal lymph node dissection in patients with high risk testicular Cancer.
- Surgical apgar outcome score: perioperative risk assessment for radical cystectomy.
- Solitary adrenal metastatic lesion in a patient with a history of prostate Cancer.
- Predictors of patient preferences and treatment choices for localized prostate Cancer.
- Management of the incidental Renal mass.
- Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical Prostatectomy.
- By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch?
- New frontiers in nanotechnology for Cancer treatment.
- Decision analysis using individual patient preferences to determine optimal treatment for localized prostate Cancer.
- The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing a...
- Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk pro...
- Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor.
- Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate Cancer.
- Radical prostatectomy for high-grade prostate Cancer.
- Development of an integrated prostate Cancer research information system.
- Targeted nanoparticle-aptamer bioconjugates for Cancer chemotherapy in vivo.
- Evidence to support a continued stage migration and decrease in prostate Cancer specific mortality.
- Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate Cancer.
- Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis.
- Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry.
- Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
- PSA outcome following radical prostatectomy for patients with localized prostate Cancer stratified by prostatectomy findings and the preoperative PSA level.
- Cisplatin-induced apoptosis in human malignant Testicular germ cell lines depends on MEK/ERK activation.
- OCT4 staining in testicular tumors. A sensitive and Specific marker for seminoma and embryonal carcinoma.
- Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients.
- Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate Cancer.
- Intertubular growth in pure seminomas: associations with poor prognostic parameters.
- Low p21Waf1/Cip1 Protein Level Sensitizes Testicular Germ Cell Tumor Cells to Fas-Mediated Apoptosis.
- Somatic mutations of KIT in familial Testicular germ cell tumours.
- Familial risk in testicular Cancer as a clue to a heritable and environmental aetiology.
- Predictors of short postoperative Prostate-specific antigen doubling time for patients diagnosed during PSA era.
- The management of nonseminomatous testicular Cancer.
- Invasion of seminal vesicles by adenocarcinoma of the Prostate: PSA outcome determined by preoperative and postoperative factors.
- Prostate carcinoma tissue proteomics for biomarker discovery.
- Comparing PSA outcome after radical Prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adeno...
- Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.
- Is there an increased incidence of contralateral testicular Cancer in patients with intratesticular microlithiasis?
- Malignant germ cell tumors: clinical characteristics, treatment, and outcome. A report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu area, Ja...
- Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided Prostate brachytherapy with or without neoadjuvant external beam radiation therapy.
- Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center.
- Role of P53 and MDM2 in treatment response of human germ cell tumors.
- Late recurrence in 1263 men with Testicular germ cell tumors. Multivariate analysis of risk factors and implications for management.
- Management preferences following radical inguinal orchidectomy for Stage 1 Testicular seminoma in Australasia.
- Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
- Can the core length involved with prostate Cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?
- Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate Cancer during the prostate-specific antigen era.
- By the way, doctor. Ultrasound treatment for Peyronie's disease? I have Peyronie's disease. Nothing seems to help. But I've heard about a new treatment that involves s...
- Editorial: testis Cancer--paradigm for reduction in morbidity without sacrifice of efficacy.
- Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site,- and histopathology-related differences--a Children's Cancer Group Study.
- MAGE-A4, a germ cell Specific marker, is expressed differentially in testicular tumors.
- Testicular function following chemotherapy.
- Establishment of a Testicular carcinoma cell line producing alpha-fetoprotein.
- Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular Cancer.
- Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate Cancer diagnosed duri...
- Predictive factor analysis as the basis for the clinical utility of percent positive prostate biopsies in patients with intermediate-risk prostate Cancer.
- Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for Prostate-only radiation therapy.
- Biochemical outcome after radical Prostatectomy or external beam radiation therapy for patients with clinically localized Prostate carcinoma in the Prostate specific a...
- Impact of race on Prostate-specific antigen outcome after radical Prostatectomy for clinically localized adenocarcinoma of the Prostate.
- Percentage of core lengths involved with prostate Cancer: does it add to the percentage of positive prostate biopsies in predicting postoperative prostate-specific ant...
- Lower Prostate specific antigen outcome than expected following radical Prostatectomy in patients with high grade Prostate and a prostatic specific antigen level of 4 ...
- Gene expression correlates of clinical prostate Cancer behavior.
- Tumor detection by virtual cystoscopy with color mapping of Bladder wall thickness.
- Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort.
Schools
University of Texas At Galveston Medical Branch
University Of California Los Angeles
Procedures Preformed
- Cystectomy
- Cystometry
- Cystotomy
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- View All
Conditions Treated
- Bladder Cancer
- Bladder Infection
- Blood in Urine (Hematuria)
- Chronic Kidney Diseases
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- America's Top Doctors
- Boston Magazine
- America's Top Doctors for Cancer
- Boston Herald
- Fellow (FACS)
- Top MD
- Super Doctor
Education
-
UCLA Medical Center -
University of Texas Medical Branch
Hospital
-
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1396797619 | |
| NPPES Provider LastName | RICHIE | |
| NPPES Provider FirstName | JEROME | |
| NPPES Provider ZIPCode | 02115 | |
| NPPES Provider State | MA | |
| Specialty Description | Urology | |
| Total Claim Count | 132.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396797619 |
| Last Name Of The Provider | RICHIE |
| First Name Of The Provider | JEROME |
| View All |
Similar Doctors
|
|
Dr. Theodore J. Ongaro, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yahir A. Santiago-Lastra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rebecca S. Lavelle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Simpa S. Salami, MD |
|
|
Dr. James S. Hwong, MD |
|
|
Dr. Wilmer B. Roberts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael P. O'Leary, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evgeniy I. Kreydin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dicken S. Ko, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew A. Wagner, MD |
|
|
Dr. Francis J. McGovern, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William C. Dewolf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Balaji N. Reddy, MD |